Last updated: 2026-10-16 15:53:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Soligenix, Inc. (SNGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.36, with a market capitalization of $7.42M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.28 to $1.76. This page covers its latest market performance, valuation, price trends and company information.
$7.42M | |
$0.36 | |
$1,217.98 | |
$0.28 | |
$0.36 | |
151.52K | |
229.31K | |
-- | |
$1.76 | |
$0.28 | |
-- | |
-- |
Soligenix, Inc. (SNGX) is currently trading at $0.36 as of 2026-10-16 15:48:00, up 1.38% ($0.00) from the previous close of $0.36
During today's regular trading session, SNGX has traded between $0.28 and $1,217.98, with a trading volume of 151.52K shares. The current price is near the lower end of today's range.
Over the past seven days, Soligenix, Inc. (SNGX) moved from $0.35 to $0.36, representing a gain of 1.84% ($0.01).
The stock traded between $0.32 and $0.38 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 135.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5.4%
SNGX is currently trading at $0.36, placing it 5.4% of the way from its 52-week low of $0.28 to its 52-week high of $1.76. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Soligenix, Inc. (SNGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.